1. Home
  2. IMAB vs PIM Comparison

IMAB vs PIM Comparison

Compare IMAB & PIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMAB
  • PIM
  • Stock Information
  • Founded
  • IMAB 2014
  • PIM 1988
  • Country
  • IMAB United States
  • PIM United States
  • Employees
  • IMAB N/A
  • PIM N/A
  • Industry
  • IMAB Biotechnology: Pharmaceutical Preparations
  • PIM Finance Companies
  • Sector
  • IMAB Health Care
  • PIM Finance
  • Exchange
  • IMAB Nasdaq
  • PIM Nasdaq
  • Market Cap
  • IMAB 200.9M
  • PIM 161.4M
  • IPO Year
  • IMAB 2020
  • PIM N/A
  • Fundamental
  • Price
  • IMAB $2.11
  • PIM $3.32
  • Analyst Decision
  • IMAB Strong Buy
  • PIM
  • Analyst Count
  • IMAB 3
  • PIM 0
  • Target Price
  • IMAB $6.33
  • PIM N/A
  • AVG Volume (30 Days)
  • IMAB 392.1K
  • PIM 57.5K
  • Earning Date
  • IMAB 05-15-2025
  • PIM 01-01-0001
  • Dividend Yield
  • IMAB N/A
  • PIM 8.28%
  • EPS Growth
  • IMAB N/A
  • PIM N/A
  • EPS
  • IMAB N/A
  • PIM 0.05
  • Revenue
  • IMAB N/A
  • PIM N/A
  • Revenue This Year
  • IMAB N/A
  • PIM N/A
  • Revenue Next Year
  • IMAB N/A
  • PIM N/A
  • P/E Ratio
  • IMAB N/A
  • PIM $63.80
  • Revenue Growth
  • IMAB N/A
  • PIM N/A
  • 52 Week Low
  • IMAB $0.60
  • PIM $2.90
  • 52 Week High
  • IMAB $3.08
  • PIM $3.28
  • Technical
  • Relative Strength Index (RSI)
  • IMAB 49.47
  • PIM 45.69
  • Support Level
  • IMAB $2.01
  • PIM $3.30
  • Resistance Level
  • IMAB $2.25
  • PIM $3.34
  • Average True Range (ATR)
  • IMAB 0.13
  • PIM 0.03
  • MACD
  • IMAB -0.03
  • PIM -0.01
  • Stochastic Oscillator
  • IMAB 25.00
  • PIM 37.44

About IMAB I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

About PIM Putnam Master Intermediate Income Trust

Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.

Share on Social Networks: